Revisiting the effects of CMV on long-term transplant outcome

Current Opinion in Organ Transplantation

Volumn 15, Issue 4, 2010, Pages 492-498

  Baron, Christophe ^a,b   Forconi, Catherine ^a   Lebranchu, Yvon ^a,b  

^a FHU SUPORT   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

cytomegalovirus; graft outcome; indirect effects; pathogenesis; prevention

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; GANCICLOVIR; GLYCOPROTEIN B; I KAPPA B KINASE INHIBITOR; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEFLUNOMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR A; RAPAMYCIN; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT;

CD8+ T LYMPHOCYTE; CYTOMEGALOVIRUS INFECTION; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFLAMMATION; INFLAMMATORY CELL; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NONHUMAN; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PROPHYLAXIS; REVIEW; SMOOTH MUSCLE FIBER; TELOMERE; TREATMENT DURATION; VASCULITIS; VIRUS REACTIVATION; VIRUS REPLICATION; ALLOTRANSPLANTATION; ANIMAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNOLOGY; TREATMENT OUTCOME; VIROLOGY; VIRUS ACTIVATION;

ANIMALS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 77955188045     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32833bd3b5     Document Type: Review

References (53)

1. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. J Am Med Assoc 1989; 261:3607-3609.
2. Carstens J, Andersen HK, Spencer E, Madsen M. Cytomegalovirus infection in renal transplant recipients. Transpl Infect Dis 2006; 8:203-212.
3. Pereyra F, Rubin RH. Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis 2004; 17:357-361.
4. Li L, Chaudhuri A, Weintraub LA, et al. Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation. Pediatr Transplant 2007; 11:187-195.
5. Streblow DN, Orloff SL, Nelson JA. Acceleration of allograft failure by cytomegalovirus. Curr Opin Immunol 2007; 19:577-582.
6. Davison AJ, Dolan A, Akter P, et al. The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome. J Gen Virol 2003; 84:17-28.
7. Chen DH, Jiang H, Lee M, et al. Three-dimensional visualization of tegument/ capsid interactions in the intact human cytomegalovirus. Virology 1999; 260:10-16.
8. Jarvis MA, Nelson JA. Human cytomegalovirus tropism for endothelial cells: not all endothelial cells are created equal. J Virol 2007; 81:2095-2101.
9. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus- specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202:673-685.
10. Valantine HA. Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant 'atheroma'. Transplantation 2003; 76:891-899.
11. Valantine HA. The role of viruses in cardiac allograft vasculopathy. Am J Transplant 2004; 4:169-177.
12. Tu W, Potena L, Stepick-Biek P, et al. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation 2006; 114:1608-1615.
13. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. J Am Med Assoc 1989; 261:3561-3566.
14. Koskinen P, Lemstrom K, Bruggeman C, et al. Acute cytomegalovirus infection induces a subendothelial inflammation (endothelialitis) in the allograft vascular wall. A possible linkage with enhanced allograft arteriosclerosis. Am J Pathol 1994; 144:41-50.
15. Cook CH, Bickerstaff AA, Wang JJ, et al. Disruption of murine cardiac allograft acceptance by latent cytomegalovirus. Am J Transplant 2009; 9:42-53.
16. van de Berg PJ, Griffiths SJ, Yong SL, et al. Cytomegalovirus infection reduces telomere length of the circulating T cell pool. J Immunol 184:3417-3423.
17. Samani NJ, Boultby R, Butler R, et al. Telomere shortening in atherosclerosis. Lancet 2001; 358:472-473.
18. Cawthon RM, Smith KR, O'Brien E, et al. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 2003; 361:393-395.
19. Brouilette SW, Moore JS, McMahon AD, et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 2007; 369:107-114.
20. Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4):S78-S86.
21. Fishman JA, Emery V, Freeman R, et al. Cytomegalovirus in transplantation: challenging the status quo. Clin Transplant 2007; 21:149-158.
22. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66:329-337.
23. Krieger NR, Becker BN, Heisey DM, et al. Chronic allograft nephropathy uniformly affects recipients of cadaveric, nonidentical living-related, and livingunrelated grafts. Transplantation 2003; 75:1677-1682.
24. Reinke P, Fietze E, Ode-Hakim S, et al. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 1994; 344:1737-1738.
25. Helantera I, Koskinen P, Tornroth T, et al. The impact of cytomegalovirus infections and acute rejection episodes on the development of vascular changes in 6-month protocol biopsy specimens of cadaveric kidney allograft recipients. Transplantation 2003; 75:1858-1864.
26. Liapis H, Storch GA, Hill DA, et al. CMV infection of the renal allograft is much more common than the pathology indicates: a retrospective analysis of qualitative and quantitative buffy coat CMV-PCR, renal biopsy pathology and tissue CMV-PCR. Nephrol Dial Transplant 2003; 18:397-402.
27. Reischig T, Nemcova J, Vanecek T, et al. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus preemptive therapy in renal transplant recipients. Antivir Ther 15:23-30.
28. Helantera I, Koskinen P, Finne P, et al. Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transpl Int 2006; 19:893-900.
29. Kumar D, Chernenko S, Moussa G, et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009; 9:1214-1222.
30. Nickel P, Bold G, Presber F, et al. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function. Transpl Immunol 2009; 20:238-242.
31. Simon CO, Holtappels R, Tervo HM, et al. CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation. J Virol 2006; 80:10436-10456.
32. Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8:975-983.
33. Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4:928-936.
34. Valantine HA, Gao SZ, Menon SG, et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999; 100:61-66.
35. Potena L, Grigioni F, Magnani G, et al. Prophylaxis versus preemptive anticytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant 2009; 28:461-467.
36. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10:1228-1237.
37. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349:847-858.
38. Hill JA, Hummel M, Starling RC, et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 2007; 84:1436-1442.
39. Haririan A, Morawski K, West MS, et al. Sirolimus exposure during the early posttransplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients. Clin Transplant 2007; 21:466-471.
40. Buchler M, Caillard S, Barbier S, et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7:2522-2531.
41. Marty FM, Bryar J, Browne SK, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2007; 110:490-500.
42. Soroceanu L, Akhavan A, Cobbs CS. Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature 2008; 455:391-395.
43. Kudchodkar SB, Yu Y, Maguire TG, Alwine JC. Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase. J Virol 2004; 78:11030-11039.
44. Kudchodkar SB, Yu Y, Maguire TG, Alwine JC. Human cytomegalovirus infection alters the substrate specificities and rapamycin sensitivities of raptor- and rictor-containing complexes. Proc Natl Acad Sci U S A 2006; 103:14182-14187.
45. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098-1101.
46. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005; 17:596-603.
47. Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460:108-112.
48. Chong AS, Zeng H, Knight DA, et al. Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. Am J Transplant 2006; 6:69-75.
49. Elder RT, Xu X, Williams JW, et al. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J Immunol 1997; 159:22-27.
50. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNFinduced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 2000; 165:5962-5969.
51. Caposio P, Musso T, Luganini A, et al. Targeting the NF-kappaB pathway through pharmacological inhibition of IKK2 prevents human cytomegalovirus replication and virus-induced inflammatory response in infected endothelial cells. Antiviral Res 2007; 73:175-184.
52. Hoffmann TW, Halimi JM, Buchler M, et al. Association between a polymorphism in the human programmed death-1 (PD-1) gene and cytomegalovirus infection after kidney transplantation. J Med Genet 47:54-58.
53. Hoffmann TW, Halimi JM, Buchler M, et al. Association between a polymorphism in the IL-12p40 gene and cytomegalovirus reactivation after kidney transplantation. Transplantation 2008; 85:1406-1411.